Canada Spends Logo

Explore our Budget 2026 analysis

Program directory · Health Canada

Thalidomide

Department
Health Canada
Program code
BVG15 (H)
Core responsibility
Health Care Systems
In Departmental Plans
2018-19 – 2022-23 · Appeared and later dropped

What it does

One of the key priorities for the federal government is to provide Canadians with affordable, sustainable and efficient health care systems that take into account their specific needs. The Canadian Thalidomide Survivors Support Program (CTSSP) is intended to contribute to meeting the lifetime needs of Canadian thalidomide survivors so that they may age with dignity. Thalidomide was a drug marketed and approved in Canada in the early 1960's as a sedative but was used off label to treat morning sickness in pregnant women. Tragically, when taken in the first trimester of pregnancy, the drug had devastating consequences which led to miscarriages, birth defects and even death. The CTSSP uses a probability-based medical assessment process to confirm eligibility under the program. It provides ongoing assistance to Canadian thalidomide survivors based on their level of disability, as well as access to an Extraordinary Medical Assistance Fund (EMAF). The EMAF helps pay for home and vehicle adaptations or specialized surgery not covered by other provincial/territorial health plans, as well as some ongoing costs such as physiotherapy, chiropractic care and attendant services.

Source: the department's Program Inventory, via GC InfoBase.

History and lineage

First appears in GC InfoBase's actual spending by program in 2018-19. The data does not record when a program was created; it may be older than its first appearance here, which is limited by the sources (program spending starts in 2010-11, Departmental Plans in 2018-19).

2018-192019-202020-212021-222022-232023-242024-25Thalidomide 2018-19: $9.7MThalidomide 2019-20: $28.8MThalidomide 2020-21: $10.8MThalidomide 2021-22: $12.9MThalidomide 2022-23: $13.5MThalidomide 2023-24: $15MThalidomide 2024-25: $15.3MThalidomide
Bars: spending by fiscal year (dark: actual; light: actual restated on the 2017-18 program structure; outlined: the latest plan's forecast; grey: related programs). Bands: each program in the lineage over the years it has data.
ProgramRelationYears with dataActual spending over those years
ThalidomideThis program2018-19 – 2024-25$75.7M

No earlier or later program in the same department has a similar name.

Significant changes in scope and budget

Detected from the data: renames between plans, programs it appears to replace, merge with or split into (matched by name), year-over-year changes in spending of at least 25% and $5M, or in employees of at least 20% and 25 FTEs, linked budget measures, and results indicators added or dropped.

YearWhat changedSource
2019-20Spending $28.8M, against $9.7M in 2018-19 (+196%).Actual spending (GC InfoBase)
2020-21Spending $10.8M, against $28.8M in 2019-20 (−63%).Actual spending (GC InfoBase)

Success criteria

The program's indicators from its department's Departmental Results Framework: the target set in each year's plan, and the result reported the following year. Source: GC InfoBase.

Historical: targets against results

Percentage of survivors reporting slightly better or much better ability to age with dignity
Expected result: Thalidomide Survivors age with dignity
75.7%2018-19✓ met88%2019-20✓ met87%2020-21✓ met96%2021-22✓ met94%2022-23✓ met

Bars: result reported. Dashed line: target.

Report yearTargetDueResultStatus
2018-1970% – 90%201975.7%Met
2019-20≥ 80%202088%Met
2020-21≥ 80%202187%Met
2021-22≥ 80%202296%Met
2022-23≥ 85%202394%Met

Current: the 2026-27 plan's targets

No indicators in the 2026-27 plan.

Future goals: targets due after 2026-27

No targets with a later due date.

Spending and employees: planned against actual

Spending

2018-19: $8.5M2018-19: $9.7M2018-192019-20: $36.3M2019-20: $28.8M2019-202020-21: $20.2M2020-21: $10.8M2020-212021-22: $14.6M2021-22: $12.9M2021-222022-23: $19.6M2022-23: $13.5M2022-232023-24: $15M2023-242024-25: $15.3M2024-25
Outlined bar: planned in that year's Departmental Plan (dashed: the latest plan, for years not yet reported). Filled bar: actual.
Show the numbers
Fiscal yearPlannedActual
2018-19$8.5M$9.7M
2019-20$36.3M$28.8M
2020-21$20.2M$10.8M
2021-22$14.6M$12.9M
2022-23$19.6M$13.5M
2023-24$15M*—
2024-25$15.3M*—

Employees (FTEs)

2018-19: 02018-19: 22018-192019-20: 22019-20: 22019-202020-21: 32020-21: 22020-212021-22: 32021-22: 12021-222022-23: 32022-23: 12022-232023-24: 32023-242024-25: 32024-25
Outlined bar: planned in that year's Departmental Plan (dashed: the latest plan, for years not yet reported). Filled bar: actual.
Show the numbers
Fiscal yearPlannedActual
2018-1902
2019-2022
2020-2132
2021-2231
2022-2331
2023-243*—
2024-253*—

Planned spending, plan by plan

Each row is one year's Departmental Plan and its forecast for the next three fiscal years; read a column down to see how the forecast for one year changed. The last row is what was actually spent. Click an amount for its source. Biggest changes in federal spending plans

Actual spending is from Departmental Results Reports and the Public Accounts, as published in GC InfoBase. FTEs are full-time equivalents.